Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Jane Street Group LLC acquired a new stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 19,659 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 0.07% of Vistagen Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. American Century Companies Inc. increased its holdings in shares of Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after purchasing an additional 9,984 shares during the last quarter. Blair William & Co. IL lifted its holdings in shares of Vistagen Therapeutics by 29.2% during the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after acquiring an additional 20,000 shares during the period. Valence8 US LP bought a new stake in shares of Vistagen Therapeutics during the 3rd quarter worth $103,000. Finally, HighTower Advisors LLC bought a new stake in shares of Vistagen Therapeutics during the 3rd quarter valued at approximately $64,000. 78.39% of the stock is owned by institutional investors.

Vistagen Therapeutics Stock Up 4.6 %

NASDAQ VTGN opened at $2.97 on Thursday. The business’s fifty day moving average is $2.75 and its 200 day moving average is $3.11. Vistagen Therapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $5.74. The company has a market cap of $82.69 million, a price-to-earnings ratio of -2.40 and a beta of 0.78.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.